Peptide compounds useful for modulating FGF receptor activity

US6214795A · kind A · utility

Assignee

• Praecis Pharmaceuticals, Inc. · US

Inventors

• Howard Benjamin · Lexington, US
• Ling Chai · Lexington, US
• Mark A. Findeis · Belmont, US
• William D. Goodwin · Rochester, US
• Arvind Hundal · Watertown, US
• David I. Israel · Concord, US
• Michael Kelley · Arlington, US
• Martin Patrick Keough · Lansdowne, US
• Kuanghui Lu · Brookline, US
• Farah Natoli · Georgetown, US
• Alicia Peticolas · Watertown, US
• Ethan R. Signer · Cambridge, US
• Malcolm L. Gefter · Lincoln, US

Key dates

• Filing date: Nov 12, 1996
• Grant date: Apr 10, 2001
• Expiry date: Nov 12, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides peptide compounds that bind to either a fibroblast growth factor (FGF) or a fibroblast growth factor receptor (FGFR) and, accordingly, are useful for modulating FGFR activity. Preferably, the FGFR is FGFR2-IIIC. Preferably, the FGF is basic FGF. Preferably the peptide compound comprises an amino acid sequence: (Y/F)-(L/F/I)-(R/D/E/S/Y/G)-(Q/L/Y)-Y-(M/L/K/R)-(L/M/D/E/N/S)-(R/L/S/ T)-(L/F/M/V) (SEQ ID NO: 1). The invention further comprises pharmaceutical compositions comprising the peptide compounds of the invention and a pharmaceutically acceptable carrier. The invention still further provides methods of modulating FGFR activity using the peptide compounds of the invention.